FDA-Approved PI3K Inhibitors for CLL and FL

Slides:

Advertisements

Similar presentations

Final Results of a Phase 1 Study of Idelalisib (GS-1101), a Selective Inhibitor of Phosphatidylinositol 3-Kinase p110 Delta (PI3K), in Patients with Relapsed.

Advertisements

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Campos M et al. Proc EHA 2013;Abstract B2009.

Campos M et al. Proc EHA 2013;Abstract B2009.

Idelalisib plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a.

Shustov AR et al. Proc ASH 2010;Abstract 961.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,

New Findings in Hematology: Independent Conference Coverage

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Relapsed/Refractory Follicular Lymphoma Conundrums

Peripheral T-Cell Lymphoma in 2013

Overall Program Goals. Overall Program Goals Current Approaches.

Metastatic Renal Cell Carcinoma

Prolonging Progression-Free Survival in Follicular Lymphoma

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Current and Future Goals in the Treatment of Relapsed CLL

PARP Inhibitors and Cancer: What Do You Need to Know?

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

CDK4/6 Inhibitors in Breast Cancer:

Updates in Follicular Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Novel and Emerging Approaches to Treating CLL

The Nurse View.

Activity Goals. Activity Goals Case Presentation.

Managing gBRCA-Positive Metastatic Breast Cancer

Treatment Decisions in Chemorefractory Follicular Lymphoma

Coiffier B et al. Proc ASH 2010;Abstract 857.

Updates in Lymphoma From Recent Congresses

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Targeting BTK Signaling in B-Cell Malignancies

Managing Adverse Events With New Oral Therapies in CLL

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Personalized Therapy in Relapsed or Refractory CLL

How to Select Therapy In Newly Diagnosed CLL

Myeloid Updates From the Summer Congresses

PARP Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

VOD/SOS: Aligned Education for Patients and the Interprofessional Team

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Ahmadi T et al. Proc ASH 2011;Abstract 266.

New Paradigms in M0 CRPC.

Checkpoint Inhibitors in First-Line Advanced NSCLC

How to Select Therapy in Relapsed/Refractory CLL

CDK4/6 Inhibitors.

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Clinical Focus.

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Care Team Collaboration for CAR T-Cell Therapy: Real-World Advice

PCSK9 Inhibitors and Real-World Evidence

Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.

Presentation transcript:

Using PI3K Inhibitors for Relapsed/Refractory CLL and Follicular Lymphoma

FDA-Approved PI3K Inhibitors for CLL and FL

Idelalisib Registration Trial for R/R FL (101-09)

101-09: Best Overall Response

101-09: Other Key Efficacy Endpoints

101-09: Efficacy in Early Relapsed FL Subset

101-09: Most Common Grade 3/4 AEs

Idelalisib Registration Trial for R/R CLL (116)

Study 116: Overall Response Rate

Study 116: Progression-Free Survival

Study 116: Overall Survival

Common Toxicities Associated With Idelalisib

Copanlisib Registration Trial for R/R FL: CHRONOS-1

CHRONOS-1: ORR

CHRONOS-1: Other Key Efficacy Endpoints

CHRONOS-1: Most Common Grade > 3 AEs

Duvelisib Registration Trial for R/R CLL: DUO

DUO: PFS

DUO: PFS in Patients with ≥ 2 Prior Therapies

DUO: Lymph Node Responses

Duvelisib Registration Trial for R/R FL: DYNAMO

DYNAMO: Efficacy Results

Common Toxicities Associated With Duvelisib

AE Management Strategies

AE Management Strategies (cont)

Current Challenges/Unanswered Questions

Goals and Future Directions

Conclusions

Abbreviations